Adam Townsend: Yes, thanks Anupam. So obviously the last update to our market research was in August and that showed similar results as to the research that we shared in on the Q2 call. Now I think we’re super encouraged to see continued enthusiasm for SYFOVRE from physicians. We’ve started to see new physicians start SYFOVRE start new patients and one metric I absolutely love and I think it’s been a really powerful metric for us is since launch we have had double digit numbers of new accounts signed for SYFOVRE for the first time every week and that’s continued since launch. That shows you a little bit of the sentiment of physicians that we’re being transparent, we’re sharing with them, we’re being open and I think it’s driving the continued growth that you’re seeing from our results.
We have seen totally honestly we’ve seen some physicians become a bit more conservative. For example, many physicians are now starting the worst eye first and also they’re not doing bilateral injections as their first injections. We do still see bilateral injections being done, but they’re being a bit more thoughtful in how they approach it. But the segments from the market research we’re making in grounds in each of those one third segments, I think we’re really, really driving demand and I think you’re seeing the results of that in the number of patients that are choosing to use SYFOVRE.
Anupam Rama: Thanks so much for taking our question.
Cedric Francois: Thank you, Anupam.
Operator: Thank you. And our next question is coming from the line of Colleen Kusy with Baird. Your line is open.
Cedric Francois: Colleen, I don’t think we can hear you.
Operator: Please check your mute button.
Cedric Francois: I don’t think we can hear you, Colleen.
Operator: Okay. I’ll go on to the next question. Our next question coming from the line of Yigal Nochomovitz with Citigroup. Your line is open.
Yigal Nochomovitz: Hi, Cedric and team. Thank you for taking the question. I had one on IC-MPGN and C3G. So for that the standing you showed in the slide, was that an IC-MPGN patient or C3G patient? And then more broadly, would you expect pegcetacoplan to behave similarly in each indication? And then as regards VALIANT, could you talk about what level of proteinuria reduction would be considered clinically meaningful and will there be any interim analysis of that trial before the three 3Q 2024 top line? Thank you.
Cedric Francois: Thank you so much, Yigal and thank you for that question. So that was a C3G patient that you saw that image from and I cannot overemphasize how meaningful that histopath is, right? So just as a reminder for those that are not familiar with this, in C3G and IC-MPGN you get a deposition of C3 covalently bound, so irreversibly attached to the cells in the glomerulus. For these, for those deposits to go away you need to have healthy cells that can actually internalize that C3 product and process it properly. So for us to see these improvements over the course of three months is actually really unbelievable. And this isn’t a post-transplant situation. So these are actually patients that were transplanted and that had recurrence of the disease.
So needless to say, really, really meaningful to this population. We see these effects both in C3G and in IC-MPGN and again as mentioned this is a very important segment as well in the post-transplant setting. As it relates to VALIANT, there’s no interim readout. There’s going to be six-month readout and we will consider 50% reduction in proteinuria to be clinically meaningful.
Yigal Nochomovitz: Great. Thank you, Cedric.
Cedric Francois: Thank you, Yigal.
Operator: Thank you. And our next question is coming from the line of Steven Seedhouse with Raymond James. Your line is open.
Steven Seedhouse: Good morning. Thanks so much. I had three questions on SYFOVRE. First is just on if you expect a label amendment at some point and if so, would that include just retinovasculitis update or would you also look to add some GALE data or some of the visual function data that you noted? Second question is Astellas actually provided peak sales guidance as well, I think about U.S.$1.3 billion to U.S.$2.6 billion. Curious if you’re modeling less similar or more for SYFOVRE? And then lastly, the 50,000 patients treated that you mentioned, I’m curious if you know or have a sense of how many are currently on treatment and can estimate basically therefore, how many discontinuations you had amid the RV disclosures, patients that you might be able to bring back to SYFOVRE? Thank you.
Cedric Francois: Thank you so much, Steve. I will take the first question and then hand the other two over to Adam. As it relates to the label, so I think we should expect that there will be a label change and an update at some point. I think it’s noteworthy, right that it hasn’t happened, which is again a reflection of the fact that we have a stable situation with a very rare event that I think the FDA along with us is tracking before we get to a label change. So that’s, something to be followed as far as it relates to what that will be, that of course we don’t know yet. Adam, can you take the next two?
Adam Townsend: Yes, thanks, Steve. So obviously, we don’t guide, but we — with 5 million GA patients worldwide, we think it is a very sizable market. It’s probably the best way of me answering that question. And then the third part of your question, of the 50,000 patients currently on SYFOVRE, we think discontinuations is very low at the moment. We obviously did see some discontinuations during the retinal vasculitis phase, but we think it’s very low because it’s early in launch. And I think if you look now as a metric in October demand trajectory was back to July levels. So I think again I think we expect to see all of the new patients that are starting and all the continued patients to start to benefit from this treatment and try and stay on it. Patients are incredibly motivated. But short answer is discons we believe are quite low during this time period especially now we’re back to the growth trajectory.
Steven Seedhouse: Thanks, Adam. Just to clarify, so I think I misheard, so 50K is the current patients on SYFOVRE estimate?
Adam Townsend: All right. Thanks so much.
Cedric Francois: Thank you.
Operator: Thank you. One moment for our next question. And our next question is coming from the line of Phil Nadeau with TD Cowen. Your line is open.
Phil Nadeau: Good morning. Thanks for taking our questions. A question is on the rate of vasculitis, do you expect to present any updated rate or number of cases at the AAO meeting this weekend? Do you expect ASRS to make a presentation on their evaluation of vasculitis this weekend? And then going forward when could we expect future updates? Is there a cadence that you’d be willing to guide to like once a quarter or just that significant medical meetings or something like that? Thanks.
Cedric Francois: Thank you, Phil. So I think it’s, you know what’s really important here is that this rate is constant, is under control and has remained unchanged. I think that is really something. So we’re going to stop talking about individual cases because frankly that’s not an effort that we think is fruitful. To put this in perspective, the last case of a patient with geographic atrophy that was reported to us with vasculitis is already from September first, right. So we had that case. With a non-GA patient on September 22nd, but that’s been it. So again, we keep tracking all of this. We will report on this if there are changes, but we are not going to do this on a case by case basis. Then as it relates to ASRS, Caroline can briefly speak to this because we’ve been collaborating very closely with them.